Lyka Labs Ltd

Lyka Labs Ltd

₹ 117 0.94%
10 Jun - close price
About

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]

Key Points

Business Overview:[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.

  • Market Cap 415 Cr.
  • Current Price 117
  • High / Low 177 / 90.2
  • Stock P/E 52.3
  • Book Value 29.0
  • Dividend Yield 0.00 %
  • ROCE 9.93 %
  • ROE 9.24 %
  • Face Value 10.0

Pros

  • Company has reduced debt.

Cons

  • Stock is trading at 4.02 times its book value
  • Company has a low return on equity of -0.48% over last 3 years.
  • Company might be capitalizing the interest cost
  • Debtor days have increased from 93.7 to 114 days.
  • Working capital days have increased from 68.9 days to 102 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
35.19 27.49 25.53 17.82 22.24 22.88 27.99 32.56 27.77 30.11 41.16 33.80 33.43
22.59 21.18 20.50 15.61 18.94 20.24 23.82 25.69 25.75 26.40 36.21 28.61 29.35
Operating Profit 12.60 6.31 5.03 2.21 3.30 2.64 4.17 6.87 2.02 3.71 4.95 5.19 4.08
OPM % 35.81% 22.95% 19.70% 12.40% 14.84% 11.54% 14.90% 21.10% 7.27% 12.32% 12.03% 15.36% 12.20%
-2.27 0.95 0.98 -5.95 0.02 0.38 -0.18 0.54 0.32 0.56 0.03 0.83 0.82
Interest 2.99 2.91 3.03 3.08 2.85 1.35 1.19 1.28 1.07 0.65 0.54 0.61 0.47
Depreciation 9.46 3.59 3.62 3.47 3.47 3.47 3.59 2.84 2.90 1.76 1.76 1.83 1.42
Profit before tax -2.12 0.76 -0.64 -10.29 -3.00 -1.80 -0.79 3.29 -1.63 1.86 2.68 3.58 3.01
Tax % 607.08% 6.58% -46.88% 2.24% 0.00% 7.22% -22.78% 38.60% 28.22% 30.65% 28.36% 24.30% 32.89%
-15.07 0.60 -0.38 -10.42 -3.01 -1.85 -0.49 1.78 -2.09 1.44 2.10 2.70 2.03
EPS in Rs -5.25 0.21 -0.13 -3.63 -0.98 -0.56 -0.15 0.54 -0.63 0.40 0.59 0.76 0.57
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Jun 2014 15m Jun 2015 Mar 2016 9m Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
119 166 130 110 60 71 61 86 194 93 111 138
111 139 110 87 63 73 65 67 93 76 95 121
Operating Profit 8 28 20 23 -4 -2 -4 20 101 17 16 18
OPM % 7% 17% 16% 21% -6% -3% -6% 23% 52% 18% 14% 13%
25 4 8 -2 4 1 -30 0 -4 -4 1 2
Interest 27 24 15 19 10 7 20 26 20 12 5 2
Depreciation 9 11 9 10 11 7 8 8 17 14 13 7
Profit before tax -3 -3 4 -8 -20 -15 -62 -14 59 -13 -1 11
Tax % 45% 31% -5% -19% -5% -59% 1% -29% 35% -0% 182% 29%
-5 -5 4 -7 -19 -6 -63 -10 38 -13 -3 8
EPS in Rs -3.05 -2.29 1.67 -2.51 -6.14 -1.97 -21.10 -4.03 13.59 -4.30 -0.75 2.22
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 2%
5 Years: 18%
3 Years: -11%
TTM: 25%
Compounded Profit Growth
10 Years: 9%
5 Years: 18%
3 Years: -43%
TTM: 375%
Stock Price CAGR
10 Years: 7%
5 Years: 47%
3 Years: -4%
1 Year: 9%
Return on Equity
10 Years: %
5 Years: %
3 Years: 0%
Last Year: 9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 22 22 22 22 28 28 29 29 29 31 33 36
Reserves 30 20 22 16 21 15 -43 -54 -15 15 35 68
164 137 121 126 113 96 141 163 130 75 59 39
113 100 77 88 67 76 73 52 42 31 30 33
Total Liabilities 329 279 242 252 229 216 200 190 186 152 157 176
162 122 104 133 116 108 105 98 94 68 58 86
CWIP 22 27 30 24 28 31 28 26 18 16 23 0
Investments 0 0 0 0 0 0 0 0 0 0 0 0
145 130 107 94 85 77 68 66 74 67 76 90
Total Assets 329 279 242 252 229 216 200 190 186 152 157 176

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
89 27 12 31 11 27 5 9 79 9 2 2
-57 37 17 -13 -3 -4 -0 -0 -6 7 -9 -12
-26 -60 -30 -19 -10 -23 3 -12 -63 -22 2 5
Net Cash Flow 6 4 -1 -0 -3 -1 9 -3 10 -5 -6 -5

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 209 124 121 97 125 75 48 37 35 79 89 114
Inventory Days 91 77 56 90 139 65 69 41 56 68 78 82
Days Payable 363 220 218 266 301 216 192 141 96 91 98 98
Cash Conversion Cycle -64 -18 -41 -79 -37 -75 -76 -63 -5 55 68 97
Working Capital Days -106 -88 -75 -191 -456 -181 -156 -71 6 34 71 102
ROCE % 2% 10% 7% 9% -8% -5% -6% 10% 61% 5% 4% 10%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
47.80% 47.58% 47.58% 51.00% 54.58% 54.81% 54.81% 54.81% 58.11% 58.11% 58.11% 58.16%
0.76% 0.57% 0.37% 0.18% 0.17% 0.18% 0.17% 0.17% 0.15% 0.15% 0.15% 0.24%
3.99% 4.00% 4.00% 3.74% 0.41% 0.41% 0.62% 0.81% 0.75% 0.66% 0.66% 0.66%
47.45% 47.85% 48.05% 45.08% 44.84% 44.61% 44.41% 44.21% 40.99% 41.08% 41.07% 40.93%
No. of Shareholders 26,96928,43328,51526,82027,20226,65226,42225,71725,71628,94329,09928,472

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents